HomeCompareESALF vs BTI

ESALF vs BTI: Dividend Comparison 2026

ESALF yields 3.60% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTI wins by $12.4K in total portfolio value
10 years
ESALF
ESALF
● Live price
3.60%
Share price
$30.00
Annual div
$1.08
5Y div CAGR
0.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$474.23
Full ESALF calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — ESALF vs BTI

📍 BTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESALFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESALF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESALF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESALF
Annual income on $10K today (after 15% tax)
$306.00/yr
After 10yr DRIP, annual income (after tax)
$403.10/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, BTI beats the other by $1,978.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESALF + BTI for your $10,000?

ESALF: 50%BTI: 50%
100% BTI50/50100% ESALF
Portfolio after 10yr
$31.6K
Annual income
$1,638.25/yr
Blended yield
5.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ESALF
No analyst data
Altman Z
2.9
Piotroski
7/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESALF buys
0
BTI buys
0
No recent congressional trades found for ESALF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESALFBTI
Forward yield3.60%5.40%
Annual dividend / share$1.08$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0.4%11.3%
Portfolio after 10y$25.4K$37.8K
Annual income after 10y$474.23$2,802.29
Total dividends collected$4.2K$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ESALF vs BTI ($10,000, DRIP)

YearESALF PortfolioESALF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$11,061$361.44$11,301$601.08$240.00BTI
2$12,211$375.14$12,799$706.58$588.00BTI
3$13,454$388.58$14,527$832.38$1.1KBTI
4$14,798$401.74$16,527$982.75$1.7KBTI
5$16,248$414.60$18,846$1,162.95$2.6KBTI
6$17,813$427.16$21,545$1,379.49$3.7KBTI
7$19,499$439.41$24,694$1,640.41$5.2KBTI
8$21,315$451.34$28,378$1,955.69$7.1KBTI
9$23,270$462.94$32,702$2,337.79$9.4KBTI
10$25,373$474.23$37,794$2,802.29$12.4KBTI

ESALF vs BTI: Complete Analysis 2026

ESALFStock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Full ESALF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ESALF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESALF vs SCHDESALF vs JEPIESALF vs OESALF vs KOESALF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.